integrated drug discovery

Discover a comprehensive suite of capabilities to propel your drug discovery programme from target validation to IND submission. We offer more than just multiple services. Our integrated approach combines deep scientific knowledge, expert management and a thorough understanding of the drug discovery challenges.

o2h discovery IDD

(o2h discovery’s Integrated Drug Discovery Process)

strategic partnership

Accelerated Discovery Efforts: Our optimised processes and cutting-edge technologies ensure reduced cycle times, propelling your project forward.
Hit to Pre-Clinical Progression: Proven track record of advancing hit compounds to preclinical candidates.
Innovation and Delivery: Our problem-solving mindset drives consistent results for our collaborators.
Simplified Partnership: One-stop-shop streamlined collaboration, reducing complexity.

our approach

Full Spectrum Toolbox: Our in-house capabilities range from chemistry, in vitro biology and ADME, analytical capabilities including advanced techniques like surface plasmon resonance (SPR) and HCI (High-content imaging).
Therapeutic Foresight: With expertise in cancer biology, immuno-oncology, immunology, metabolic disorders, and CNS disease areas, we’re well-versed in critical therapeutic areas.
Swift DMT Cycles: Our mastery in medicinal chemistry and organic synthesis ensures rapid design-synthesis-test cycles for hypothesis validation and SAR construction.

our strategy

Strategic Clarity: Before initiating a screening cascade, we meticulously identify critical decision-making questions, guiding the direction of your project.
Accelerated Advancement: A focused approach speeds up project advancement while cutting down on later-stage issues, focusing efforts where they count.
Empowering Chemistry: Our medicinal chemists are driven by these decisive questions, propelling them to deliver candidate molecules with exceptional speed.

our team

Backed by over 180 years of combined experience, our diverse scientific management team spans academia, pharma, biotech, and CROs. We have ability to develop bespoke biological assays by a strong team of academics and industry trained biologists in the UK and Ahmedabad, India.

Embark on a transformative journey with o2h discovery’s integrated drug discovery services. From strategy to execution, we’re your partners in translating ideas into impactful drugs. Contact us at discovery@o2h.com to get a quote.

Sunil Shah

CEO - o2h Ventures and Co-Founder - o2h discovery

Sunil's Biography

Sunil Shah

CEO - o2h Ventures and Co-Founder - o2h discovery

A serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector. The second of these companies, Oxygen Healthcare Ltd was acquired by Piramal Enterprises Ltd (BSE: PEL). Sunil co-founded o2h ventures which involves discovery services / collaborations, seeding drug discovery, academic in-licensing and biotechnology incubation. Sunil has a degree in Biochemistry and an MBA from Cambridge University

Connect on linkedin

Prashant Shah

CEO - o2h discovery and Co-Founder - o2h group

Prashant's Biography

Prashant Shah

CEO - o2h discovery and Co-Founder - o2h group

Prashant is a serial entrepreneur in life sciences and tech in which one of those companies was acquired by a public company. He is currently active in seed investing (a portfolio of ~50 companies), product/IP development, services, and building lab/office infrastructure. The early career was with the Strategy group at Accenture. He has a BEng, an MSc, in which he worked on the Human Genome Program at the Sanger Centre, and an MPhil in Management from the Judge Institute. Prashant is also a General Partner in the o2h SEIS/EIS Human Health Funds.

Connect on linkedin

Andy Morley

Chief Scientific Officer

Andy's Biography

Andy Morley

Chief Scientific Officer

Andy is a highly experienced and accomplished Medicinal Chemist with over 25 years of experience in major pharmaceutical companies such as Sanofi-Aventis and AstraZeneca. He has extensive experience across all phases of drug discovery and has played a key role in the development of five candidates that have reached clinical trials. Andy is a prolific author and inventor, with over 55 publications and patents to his name. Since 2013, he has been working full-time with o2h Limited, where he leads the scientific evaluation of investment opportunities and provides scientific support. He has also served as CSO for two early-stage collaborations within the o2h Ventures portfolio, demonstrating his ability to successfully guide drug discovery projects from concept to clinical development.

Connect on linkedin

Nilesh Dagia

Chief Special Projects Officer

Nilesh's Biography

Nilesh Dagia

Chief Special Projects Officer

Nilesh leads the global operations of o2h group covering a wide range of innovation led investment, life-science and technology businesses. He is also overseeing the development and execution of the new o2h discovery Shirish Research Centre in Ahmedabad, India. Prior to joining o2h group, Nilesh worked with Piramal Group in various capacities including as an Alliance Manager for a risk-share oncology-based collaboration with a US Big Pharma and has also worked as the Head of Biology in Piramal Discovery solutions. Nilesh obtained his Ph.D. from Ohio University and completed a post-doc in Immunology, Stem Cells and Regenerative Medicine at Harvard Medical School. He is the author and inventor of >30 life science patents and publications. He received the Young Scientist of India award from OPPI in 2010.

Connect on linkedin

Meet our team

what our clients say

Brian Dymock

Head of QEDDI

Our relationship with o2h over many years supporting our medicinal chemistry projects in QEDDI has been highly productive. With o2h’s help we have progressed our portfolio to an advanced stage ready for partnering. We are very pleased with the efficiency, productivity and communication with o2h chemists and look forward to further positive outcomes.

Prof Kirill Alexandrov

CSIRO, QUT Synthetic Biology Alliance

We have worked with o2h team on a range of synthetic projects and had consistently positive experience .The combination of competence, effective project management and detailed documentation made us go back again and again.

Sharon Shacham

Co-Founder & MD, E44 Ventures

My relationship with o2h Discovery is now more than a decade. I have had many opportunities to collaborate with the o2h team for my drug discovery efforts at Karyopharm, Protai and Sporos Bioventures. I have always been impressed by their efficiency to deliver novel chemical compounds that helps to achieve targeted project milestones. Real time and insightful communication is also their key differentiator.

Julian Blagg

Executive Vice President, Drug Discovery

NeoPhore has worked closely with o2h for over 4 years, consistently supporting NeoPhore with small and medium scale synthesis and characterisation of novel small molecule therapeutics; work that has enabled significant Series A and Series B investment. NeoPhore highly values the synthetic expertise, efficiency, project management and clear communication at o2h. Importantly, o2h benefits from highly integrated analytical and compound purification groups to enable consistent and smooth delivery of high quality target compounds to tight deadlines. Furthermore, flexibility of resourcing at o2h is ideally suited to support an evolving small biotech company like NeoPhore.

Bharat Majeti

Head of LNP Technology, RVAC Medicines

We understand that lipid chemistry is complex and requires significant expertise in synthesis, purification, and analysis. Therefore, we looked for a competent and reliable CRO partner to support our requirements and found o2h Discovery. We have done several projects with o2h.

o2h group launched revolutionary project management app for drug discovery

o2h group launched revolutionary project management app for drug discovery. The app’s full suite of project management tools is available exclusively to live project collaborators and a lighter version is open for researchers looking for a quote for the synthesis of small molecules.